Novel therapies for Crohn's disease

Drugs of Today

Volumn 36, Issue SUPPL. G, 2000, Pages 59-68

  Rutgeerts, P ^a   Baert, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CROHN DISEASE; DISEASE CONTROL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; REMISSION;

EID: 0033676473     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Immunomodulator therapy in inflammatory bowel disease
2. Review article: Immunosuppressive therapy for inflammatory bowel disease
3. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease
4. Disease activity courses in a regional cohort of Crohn's disease patients
5. Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients
6. Frequency of glucorticosteroid resistance and dependency in Crohn's disease
7. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study
8. Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomized double blind study
9. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
10. A controlled double blind study of azathioprine in the management of Crohn's disease
11. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
12. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis
13. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
14. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience
15. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease
16. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
17. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease
18. Cancer risk from azathioprine in inflammatory bowel disease
19. 6-Mercaptopurine (6-MP) is safe therapy for child bearing patients with IBD: A case controlled study
20. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease
21. Methotrexate for the treatment of Crohn's disease
22. Final report on a placebo-controlled, double-blind, randomized trial of cyclosporin treatment in active chronic Crohn's disease
23. Low-dose cyclosporin for the treatment of Crohn's disease
24. Oral cyclosporin for chronic active Crohn's disease: A multicentre controlled trial
25. European trial of cyclosporin in chronic active Crohn's disease: A 12 month study
26. To use or not to use cyclosporin-A. That is the question
27. Rapid closure of Crohn's disease fistulas with intravenous cyclosporin A
28. Cyclosporine lacks therapeutic efficacy in highly destructive perianal Crohn's disease associated with Crohn's disease (CD)
29. Tumor necrosis factor α (TNF-α). The good, the bad and the potentially very effective
30. Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β)
31. Increased mucosal TNF-α levels and numbers of TNF-α producing cells are unique to Crohn's disease mucosal inflammation
32. Inflammatory granuloma formahon is mediated by TNF-α inducible intercellular adhesion molecule-1
33. A metalloproteinase disintegrin that releases tumour necrosis factor α from cells
34. Cloning of a desintegrin metalloproteinase that porcesses precursor tumour necrosis factor α
35. Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease
36. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF kappa beta abrogates established experimental colitis in mice
37. Construction and initial characterization of a mouse-human anti-TNF-α antibody
38. The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-α lethality in vivo Cytokine
39. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
40. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependant chronic active Crohn's disease
41. Thalidomide in Crohn's disease
42. Thalidomide in oral Crohn's disease refractory to conventional medical treatment
43. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody(cA2)
44. A multicenter tnal of cA2 anti TNF chimeric monoclonal antibody in patients with active Crohn's disease
45. A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor α for Crohn's disease
46. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
47. Infliximab for the treatment of fistulas in patients with Crohn's disease
48. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
49. Tumor necrosis factor α antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis
50. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
51. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STEMM-CD)
52. A safetym and efficacy study of recombinant human interleukin-10 (rHulL-10) treatment in 329 patients with chronic active Crohn's disease (CACD)
53. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
54. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease